Enjoy the latest issue of the Hysteroscopy Newsletter.

Dear Friends and Colleagues,

It is my great pleasure to introduce this new issue of Hysteroscopy Newsletter, focused on Asherman syndrome and intrauterine adhesions. I followed the project of Hysteroscopy Newsletter since the beginning, joining the Editorial Committee with other experts, and I am very glad to see its significant evolution: without any doubt, each new issue collects very important pieces of evidence-based information about different topics of hysteroscopy, with clear and rigorous guides for the clinical practice.

Interestingly, also the topic of this new issue underwent radical changes in the recent past. Indeed, we did giant step forwards to improve our knowledge of the etiology and etiopathogenesis of Asherman syndrome, even adding to the puzzle important elements from the molecular and cellular points of view. In addition, the availability of modern 2D and 3D ultrasound, together with the potential use of fluoroscopy, allowed a paradigm shift for a precise diagnosis of intrauterine adhesions before hysteroscopic management.

Finally, the opportunity offered by new hysteroscopic devices opened new scenarios for the treatment of this condition, although we should always keep in mind that less energy we use, better outcomes we may obtain.

As reproductive surgeons dealing mainly with infertile women, I acknowledge also the promising preliminary data about hysteroscopic-guided platelet-rich plasma injection, as potential novel treatment when the endometrium is refractory to hormonal stimuli after hysteroscopic adhesiolysis.

In summary, much more work is yet to be done in the field, but I am quite sure that our group of worldwide recognized hysteroscopists will achieve significant advancements in the next future, due to a fine-tuned ability to see over the horizon of common clinical practice.
Ad maiora!

Antonio Simone Laganà, M.D, Ph.D.
(read more in the newsletter…)


Use your login / password to gain access to the membersarea of the ISGE-site.